Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Rochester, MN
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
New Brunswick, NJ
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Albuquerque, NM
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
New York, NY
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Chapel Hill, NC
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Hershey, PA
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Hershey, PA
Click here to add this to my saved trials
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Houston, TX
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Treatment of Congenital Factor VII Deficiency
Treatment of Congenital Factor VII Deficiency. A Prospective Observational Study
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Princeton, NJ
Treatment of Congenital Factor VII Deficiency
Treatment of Congenital Factor VII Deficiency. A Prospective Observational Study
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Princeton, NJ
Click here to add this to my saved trials
Treatment of Congenital Factor VII Deficiency
Treatment of Congenital Factor VII Deficiency. A Prospective Observational Study
Status: Enrolling
Updated:  1/11/2017
Novo Nordisk Investigational Site
mi
from
Paris La défense cedex,
Treatment of Congenital Factor VII Deficiency
Treatment of Congenital Factor VII Deficiency. A Prospective Observational Study
Status: Enrolling
Updated: 1/11/2017
Novo Nordisk Investigational Site
mi
from
Paris La défense cedex,
Click here to add this to my saved trials
UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
Status: Enrolling
Updated:  1/12/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
Status: Enrolling
Updated: 1/12/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Sacramento, CA
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
San Francisco, CA
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Washington,
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Miami, FL
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Atlanta, GA
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Chicago, IL
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Newark, NJ
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Newark, NJ
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Pittsburgh, PA
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Plano, TX
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Plano, TX
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Charlottesville, VA
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Richmond, VA
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
Seattle, WA
Use of Activated Recombinant FVII in Spinal Surgery
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
Multi-center, Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven®) for Preventing Early Hematoma Growth in Acute Intracerebral Hemorrhage (ICH)
Status: Enrolling
Updated:  1/12/2017
Novo Nordisk Investigational Site
mi
from
New York, NY
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
Multi-center, Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven®) for Preventing Early Hematoma Growth in Acute Intracerebral Hemorrhage (ICH)
Status: Enrolling
Updated: 1/12/2017
Novo Nordisk Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia
Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia
Status: Enrolling
Updated:  1/17/2017
Novo Nordisk Investigational Site
mi
from
Plainsboro, NJ
Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia
Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia
Status: Enrolling
Updated: 1/17/2017
Novo Nordisk Investigational Site
mi
from
Plainsboro, NJ
Click here to add this to my saved trials
Healing Touch in Treating Patients Receiving Chemotherapy for Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Healing Touch as a Supportive Intervention for Adult Acute Leukemia Patients: A Pilot Study
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Healing Touch in Treating Patients Receiving Chemotherapy for Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Healing Touch as a Supportive Intervention for Adult Acute Leukemia Patients: A Pilot Study
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
Use of Music to Reduce Anxiety & Perceived Pain for Adult Patients With Hematological Malignancies Undergoing Bone Marrow Biopsy
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
Use of Music to Reduce Anxiety & Perceived Pain for Adult Patients With Hematological Malignancies Undergoing Bone Marrow Biopsy
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
Pharmacokinetic (PK) Analysis of a Novel Immunoassay in Hemophilia A
Status: Enrolling
Updated:  1/31/2017
Department of Biochemistry University of Vermont
mi
from
Burlington, VT
Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
Pharmacokinetic (PK) Analysis of a Novel Immunoassay in Hemophilia A
Status: Enrolling
Updated: 1/31/2017
Department of Biochemistry University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
A Pilot Study of Romidepsin for Therapy of Graft-versus-Host Disease
Status: Enrolling
Updated:  2/1/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
A Pilot Study of Romidepsin for Therapy of Graft-versus-Host Disease
Status: Enrolling
Updated: 2/1/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)
Status: Enrolling
Updated:  2/2/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)
Status: Enrolling
Updated: 2/2/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)
Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From Acute Myeloid Leukemia (AML) Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)
Status: Enrolling
Updated:  2/6/2017
MBRCC, West Virginia University
mi
from
Morgantown, WV
Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)
Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From Acute Myeloid Leukemia (AML) Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)
Status: Enrolling
Updated: 2/6/2017
MBRCC, West Virginia University
mi
from
Morgantown, WV
Click here to add this to my saved trials
Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers
Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers
Status: Enrolling
Updated:  2/6/2017
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers
Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers
Status: Enrolling
Updated: 2/6/2017
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Riley Hospital for Children at IU Health
mi
from
Indianapolis, IN
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Riley Hospital for Children at IU Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Children's Hospital at Montefiore
mi
from
Bronx, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Maimonides Medical Center
mi
from
Brooklyn, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Maimonides Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
NYU Langone Medical Center
mi
from
New York, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Mount Sinai Hospital
mi
from
New York, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
A Pharmacokinetic Study of Oral and Intravenous Clofarabine in Patients With High Risk Myelodysplasia and Acute Leukemias - Determination of Oral Bioavailability and the Effect of Cimetidine on Clofarabine Clearance
Status: Enrolling
Updated:  2/7/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
A Pharmacokinetic Study of Oral and Intravenous Clofarabine in Patients With High Risk Myelodysplasia and Acute Leukemias - Determination of Oral Bioavailability and the Effect of Cimetidine on Clofarabine Clearance
Status: Enrolling
Updated: 2/7/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  2/8/2017
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 2/8/2017
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  2/8/2017
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 2/8/2017
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  2/8/2017
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 2/8/2017
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  2/8/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 2/8/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated:  2/8/2017
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Status: Enrolling
Updated: 2/8/2017
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A
Status: Enrolling
Updated:  2/9/2017
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A
Status: Enrolling
Updated: 2/9/2017
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A
Status: Enrolling
Updated:  2/9/2017
Novo Nordisk Investigational Site
mi
from
Lexington, KY
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A
Status: Enrolling
Updated: 2/9/2017
Novo Nordisk Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A
Status: Enrolling
Updated:  2/9/2017
Novo Nordisk Investigational Site
mi
from
Baltimore, MD
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A
Status: Enrolling
Updated: 2/9/2017
Novo Nordisk Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A
Status: Enrolling
Updated:  2/9/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A
Status: Enrolling
Updated: 2/9/2017
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials